Skip to main content
Sarah M. Bartsch on Muck Rack

Sarah M. Bartsch

As seen in: National Institutes of Health, Cambridge University Press & Assessment, SAGE Publishing, JAMA (The Journal of the American Medical Association), EClinicalMedicine, The Lancet, Health Affairs, Texas Medical Center, American Journal of Preventive Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sarah M.

Contact Sarah M., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The Current and Future Burden of Long COVID in the United States

|
By Sarah M. Bartsch
| Texas Medical Center
10.1093/infdis/jiaf030 cost, economic, model, long COVID, post-COVID conditions Humans, COVID-19, United States, Cost of Illness, SARS-CoV-2, Computer Simulation, Health Care Costs, Post-Acute COVID-19 Syndrome yes Bartsch, Sarah M; Chin, Kevin L; Strych, Ulrich; et al., "The Current and Future Burden of Long COVID in the United States" (2025). Faculty, Staff and Students Publications. 6485. https://digitalcommons.library.tmc.edu/baylor_docs/6485
Open in Who Shared Issue with article?

"What Is the Economic Benefit of Annual COVID-19 Vaccination From the A" by Sarah M Bartsch, Kelly J O'Shea et al.

|
By Sarah M. Bartsch
| Texas Medical Center
Keywords Humans, COVID-19, COVID-19 Vaccines, Middle Aged, Adult, Adolescent, SARS-CoV-2, Vaccination, Cost-Benefit Analysis, Young Adult, United States, Markov Chains, Male, Female, COVID-19, vaccination, booster, individual, economic, model Abstract Background: With coronavirus disease 2019 (COVID-19) vaccination no longer mandated by many businesses/organizations, it is now up to individuals to decide whether to get any new boosters/updated vaccines going forward.
Open in Who Shared Issue with article?

"The Potential Epidemiologic, Clinical, and Economic Value of a Univers" by Sarah M Bartsch, Kelly J O'Shea et al.

|
By Sarah M. Bartsch, Kelly O'Shea, Danielle John, Ulrich Strych
| Texas Medical Center
BACKGROUND: With efforts underway to develop a universal coronavirus vaccine, otherwise known as a pan-coronavirus vaccine, this is the time to offer potential funders, researchers, and manufacturers guidance on the potential value of such a vaccine and how this value may change with differing vaccine and vaccination characteristics.
Open in Who Shared Issue with article?
See all 24 articles